Aurobindo Pharma secures FTC approval for Lannett business acquisition

What Aurobindo Pharma announced

On 19 June 2026, Aurobindo Pharma Ltd filed a Regulation 30 disclosure with the NSE and BSE stating that the United States Federal Trade Commission (FTC) has granted the necessary approval for its proposed acquisition of the Lannett business. The approval clears the way for Aurobindo Pharma USA Inc., a wholly‑owned subsidiary, to acquire 100 % of the membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.

The company indicated that, subject to the FTC clearance, it expects the transaction to close before the end of June 2026 and will update the exchanges on any further developments.

Acquisition details

• Parties involved: Aurobindo Pharma USA Inc. (buyer) and Lannett Seller Holdco, Inc. (seller). The target is Lannett Company LLC, a US‑based pharmaceutical entity.
• Structure: The acquisition will be effected by purchasing the entire membership interest of Lannett Company LLC, giving Aurobindo Pharma USA Inc. full control over the business.
• Agreement date: The definitive agreement was originally communicated in a letter dated 30 July 2025, which outlined the intent to acquire the Lannett business.
• Financial terms: The filing does not disclose the purchase price or any related consideration.

Regulatory approval

The filing confirms that the FTC, the US antitrust authority, has issued its approval on the day of filing – 19 June 2026. FTC clearance is a statutory requirement for transactions that may affect competition in the United States pharmaceutical market. By obtaining this approval, Aurobindo removes a key regulatory hurdle, allowing the parties to proceed to the closing stage without further antitrust review.

Key facts at a glance

Why this matters for investors

• Regulatory certainty: FTC approval eliminates a major antitrust risk, meaning the transaction can move to completion without additional US competition clearance.
• Strategic expansion: Acquiring Lannett’s business adds a US‑based pharmaceutical platform to Aurobindo’s portfolio, potentially broadening its product offering and market reach.
• No immediate dilution: The deal is being executed through an existing wholly‑owned subsidiary, so there is no issuance of new shares or debt disclosed in the filing.
• Financial opacity: The filing does not reveal the transaction value or financing structure, leaving the impact on cash reserves or leverage unclear.
• Pending closure: While approval is secured, the transaction still requires closing, which may be subject to customary closing conditions and any remaining regulatory consents.

Conclusion

Aurobindo Pharma Ltd has cleared the primary US antitrust hurdle for its acquisition of Lannett Company LLC, with FTC approval received on 19 June 2026. The company expects the deal to close before the end of the month and will keep the exchanges apprised of any further developments. Until the closing, the exact financial terms and post‑closing integration plans remain undisclosed.